STOK (Stoke Corp) Earnings per share increase in current year
Stoke Therapeutics (STOK) is developing RNA therapies to combat rare genetic pathologies, which confirms a shift in earnings per share compared to last year; the -3212.70 metric determines this level. Business success is based on clinical trial results and patent protection. Monetization relies on scientific collaborations and licensing agreements without conducting merger and acquisition deals.
Analytical breakdowns and data insights for company Stoke Therapeutics (STOK)
- share price and expert price forecast:
- business market valuation indicators:
- business book valuation details:
- debt burden and liquidity indicators:
Total Debt to Capital Stoke Therapeutics|STOK - Long-Term Debt to Equity|Current Liabilities to Equity Stoke Therapeutics, Inc.|STOK - Company Aggregate Debts|Debts to Book Value Stoke Therapeutics Inc|STOK - Company Long-Term Liabilities|Company Short-Term Debts Stoke Therapeutics|Intermediate Liquidity Ratio stoketherapeutics.com
- company profitability and valuation multiples indicators:
STOK - Net Profit|Company Profit Forecast Stoke Therapeutics|STOK - P/E Multiple|Projected Price to Earnings stoketherapeutics.com|STOK - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Stoke Therapeutics, Inc.|STOK - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Stoke Therapeutics|STOK - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months stoketherapeutics.com|STOK - Earnings per share growth in current year|Expected net earnings per share growth next year Stoke Therapeutics
- revenue and sales proceeds data:
Fundamental valuation:STOK Stoke Therapeutics
Stoke Therapeutics (STOK) is developing a closed RNA therapy ecosystem, where proprietary gene expression regulation creates a high dependency of clinics on the company's drugs. An analysis of the relative growth of net earnings per share over the year allows for an assessment of the monetization efficiency of this technology and the business's ability to scale profitability, which serves as a key indicator of the fundamental stability of capitalization amid market revaluation.
Key competitors
Tempus AI, Inc (TEM) - Earnings growth in current year|Earnings per share growth in current year Qiagen|IONS: Earnings per share increase in current year|Net earnings per share growth this year RGEN (Repligen)|Expected net earnings per share growth this year Avidity Biosciences Inc|Earnings growth in current year CRSP (crisprtx.com)|WGS: Earnings per share growth this year|RARE: Net earnings per share growth this year|Earnings per share trend in current year BEAM|Sarepta (SRPT) - Earnings per share growth in current year|TWST - Expected net earnings per share growth this year|Earnings per share growth in current year 10x Genomics, Inc.|NTLA: Earnings per share increase in current year|Earnings growth in current year BLFS|Wave Life Sciences - Earnings per share growth this year|Earnings growth in current year MAZE (Maze Therapeutics, Inc.)|Earnings growth in current year Sionna Pharma SION|Prime Medicine Bio - Earnings growth in current year|Earnings per share increase in current year TSHA (Taysha)|QURE: Earnings growth in current year|MGTX - Expected net earnings per share growth this year|Net earnings per share growth this year RGNX|SLDB: Earnings per share increase in current year|Earnings per share growth in current year ocugen.com (OCGN)|Expected net earnings per share growth this year PacBio Corp|Earnings per share growth in current year Benitec Biopharma BNTC|DSGN: Earnings per share growth this year|RCKT - Earnings per share growth in current year|4dmoleculartherapeutics.com (FDMT) - Net earnings per share growth this year|lexeotx.com (LXEO) - Earnings per share growth in current year|Korro Bio, Inc (KRRO) - Earnings growth in current year|EDIT (editasmedicine.com) - Earnings growth in current year|Earnings per share growth this year SLN (silence-therapeutics.com)|Earnings per share growth in current year proqr.com (PRQR)|Codexis - Earnings per share growth this year|Earnings growth in current year SGMO (Sangamo Therapeutics)|Earnings growth in current year nautilus.bio NAUT|Metagenomi Inc. - Earnings growth in current year|DTIL (Precision BioSciences Inc.) - Earnings per share growth this year|GBIO: Earnings growth in current year|Earnings per share growth rate in current year Boundless Bio, Inc (BOLD)|XCUR (Exicure) - Earnings growth in current year|Net earnings per share growth this year Imunon (IMNN)|Earnings growth in current year PHIO|Mustang Bio - Earnings per share growth this year|TransCode Therapeutics, Inc. - Net earnings per share growth this year|Expected net earnings per share growth this year Bionano Genomics, Inc. (BNGO)|APDN - Earnings per share growth in current year|Earnings per share increase in current year BLUE (Bluebird Bio)|ImmunoPrecise (IPA) - Earnings per share growth in current year|OMGA: Net earnings per one share growth for the current year|Earnings per share growth in current year Singular Genomics Systems, Inc.|Earnings growth in current year Regulus Therapeutics, Inc.|Net earnings per share growth this year SYRS (Syros)|TBIO - Earnings per share growth rate in current year|Earnings per share growth in current year TRACON Pharmaceuticals, Inc. TCON|Unity Biotechnology (UBX) - Earnings per share growth rate in current year
